13F Pro

TLSITriSalus Life Sciences, Inc.(TLSI)Stock Analysis

AI analysis on 2,800+ stocks →
Healthcare →Nasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 1826667TLSI stock profile & AI dashboard →

13F Pro Quality Score

28.3/100

Rank #2,443 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

84.4/100

Profitability

8.9/100

Balance Sheet

1.3/100

Earnings Quality

30.0/100

Free Cash Flow

8.7/100

Institutional Flow

94.6/100

Revenue Scale

9.5/100

Dilution Risk

9.1/100

TLSI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TriSalus Life Sciences, Inc. (TLSI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TLSI at 28.3/100 on a 32-signal composite quality model, placing it at rank #2,443 of 2,879 stocks — the bottom half of the AI-ranked universe. TLSI scores in the top quartile across institutional flow (94.6), revenue growth (84.4). Areas of concern include balance sheet strength (1.3) and free cash flow (8.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), TriSalus Life Sciences, Inc. reports quarterly revenue of $8.9M, net income of $1.5M, free cash flow of $-6.6M. Top institutional holders of TLSI by reported 13-F value include First Light Asset Management,, AWM Investment Company,, Nantahala Capital Management,, based on the most recent SEC filings. TLSI trades on the Nasdaq exchange and files with the SEC under CIK 1826667. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TLSI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TriSalus Life Sciences, Inc. directly from SEC EDGAR.

✦

Fun facts about TriSalus Life Sciences, Inc.

Quirks, history, and lore behind TLSI — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A small-cap U.S. medical device company listed on Nasdaq, focused on improving drug delivery to difficult-to-reach tumors.
  • 2
    The Numbers
    Revenue is in the low tens of millions of dollars annually — this is a commercial-stage company still working toward profitability, not a household name on Wall Street.
  • 3
    The History
    The company's technology traces back to work on pressure-enabled drug delivery, aiming to solve a problem oncologists have wrestled with for decades: getting chemotherapy past vascular barriers in tumors.
  • 4
    The Secret
    Its flagship platform uses increased pressure to push drugs deeper into tumor tissue — a technique called Pressure-Enabled Drug Delivery (PEDD) that standard IV infusion simply can't replicate.
  • 5
    The Lore
    Its lead device is designed specifically for liver and pancreatic cancers — some of the deadliest and hardest-to-treat malignancies — giving it a niche that larger medtech giants have largely ignored.
  • 6
    The Giveaway
    The TriNav Infusion System, a pressure-enabled catheter for hepatic artery infusion, is the centerpiece of a Colorado company whose very name hints at three vessels and a life-saving mission.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$8.9M

Net Income

Q1 2026

$1.5M

Free Cash Flow

Q1 2026

$-6.6M

Get alerted when TLSI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TriSalus Life Sciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of TLSI

Put TLSI on your watchlist

Track score changes the day TriSalus Life Sciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

META

Meta

13F Pro HomeView PricingFeatures

Is TLSI a good stock to buy?

13F Pro's AI-powered analysis of TriSalus Life Sciences, Inc. (TLSI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TLSI are available on the TLSI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TLSI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TLSI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TriSalus Life Sciences, Inc.'s investment landscape.